Pentraxin 3: A promising therapeutic target for cardiovascular diseases

Ye, Xingyan; Wang, Zheng; Lei, Wangrui; Shen, Mingzhi; Tang, Jiayou; Xu, Xuezeng; Yang, Yang; Zhang, Huan

doi:10.1016/j.arr.2023.102163

Cited by 8 publications

(3 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few years, pentraxin 3, which actively participates in various stages of atherosclerosis development, has gained attention among researchers as a new biochemical marker for the cardiovascular risk [ 9 ]. Numerous studies have shown that increased PTX3 levels are associated with the presence of high-risk plaques [ 10 , 11 , 30 ] and acute cardiovascular events [ 8 , 31 , 32 , 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

“…Notably, the study by Suzuki et al lacked information about cardiovascular disease in their participant cohort. Pentraxin 3 and its heightened levels are linked with atherosclerotic cardiovascular disease [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…The distinctive capability of pentraxin 3 to regulate local inflammation involving macrophages and smooth muscle cells has prompted research into its role in the pathogenesis of atherosclerosis and cardiovascular disease. The observed positive correlation between the PTX3 concentration and the risk of adverse outcomes in patients with coronary artery disease (CAD) suggests that PTX3 could be a valuable biomarker for cardiovascular disease [ 8 , 9 ]. Furthermore, the serum PTX3 concentration is correlated with plaque vulnerability evaluated by optical coherence tomography in individuals with coronary artery disease [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects—A Pilot Study

Hachuła,

Kosowski,

Basiak

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: The rise in global diabetes cases, reaching a staggering 529 million in 2021 from 108 million in 1980, underscores the urgency of addressing its complications, notably macrovascular ones like coronary artery, cerebrovascular, and peripheral artery diseases, which contribute to over 50% of diabetes mortality. Atherosclerosis, linked to hyperglycemia-induced endothelial dysfunction, is pivotal in cardiovascular disease development. Cytokines, including pentraxin 3 (PTX3), copeptin, lipoprotein(a) [Lp(a)], and matrix metalloproteinase-9 (MMP-9), influence atherosclerosis progression and plaque vulnerability. Inhibiting atherosclerosis progression is crucial, especially in diabetic individuals. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), increasingly used for type 2 diabetes, show promise in reducing the cardiovascular risk, sparking interest in their effects on atherogenesis. This study sought to examine the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on biomarkers that indicate the instability of atherosclerotic plaques. These biomarkers include pentraxin 3 (PTX3), copeptin (CPC), matrix metalloproteinase-9 (MMP-9), and lipoprotein(a) [Lp(a)]. Materials and Methods: A total of 34 participants, ranging in age from 41 to 81 years (with an average age of 61), who had been diagnosed with type 2 diabetes mellitus (with a median HbA1c level of 8.8%), dyslipidemia, and verified atherosclerosis using B-mode ultrasonography, were included in the study. All subjects were eligible to initiate treatment with a GLP-1 RA—dulaglutide. Results: Significant reductions in anthropometric parameters, blood pressure, fasting glucose levels, and HbA1c levels were observed posttreatment. Moreover, a notable decrease in biochemical markers associated with atherosclerotic plaque instability, particularly PTX3 and MMP-9 (p < 0.001), as well as Lp(a) (p < 0.05), was evident following the GLP-1 RA intervention. Conclusions: These findings underscore the potential of GLP-1 RAs in mitigating atherosclerosis progression and plaque vulnerability, thus enhancing cardiovascular outcomes in individuals with type 2 diabetes mellitus.

show abstract